How many insider trades does FilingIQ track for BMY?

FilingIQ tracks 2,247 Form 4 insider transactions for BMY (BRISTOL MYERS SQUIBB CO), covering filings from Mar 10, 2015 onwards. 185 of those were filed in the last 90 days.

Are BMY insiders net buyers or net sellers?

Across the full Form 4 history for BMY, 14 transactions (1%) were open-market purchases and 109 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BMY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BMY in?

BRISTOL MYERS SQUIBB CO (BMY) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $125.41B.

BMY insider trading

NYSE Healthcare

BRISTOL MYERS SQUIBB CO — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

2,247

Last 90 days

185

Buys / sells

1% / 5%

Market cap

$125.41B

About BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Company website: www.bms.com

BMY insider activity at a glance

FilingIQ has scored 2,247 insider transactions for BMY since Mar 10, 2015. The most recent filing in our index is dated May 1, 2026.

Across the full history, 14 open-market purchases and 109 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BMY insider trades is 60.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BMY trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

Top insiders trading BMY

Arduini Peter J

10 trades · score 70.0

13F funds holding BMY

Parallax Volatility Advisers, L.P.

$315.36M · 0.5% of AUM

Brandywine Global Investment Management, LLC

$168.97M · 1.4% of AUM

MIZUHO MARKETS AMERICAS LLC

$120.54M · 4.8% of AUM

Laurion Capital Management LP

$37.76M · 1.4% of AUM

SECTOR GAMMA AS

$27.17M · 6.2% of AUM

Politicians who have traded BMY

Suozzi, Thomas

U.S. Rep. , NY · 665 trades

Smith, Lamar

U.S. Rep. , TX · 495 trades

Rutherford, John

U.S. Rep. , FL · 346 trades

Sherrill, Mikie

U.S. Rep. , NJ · 256 trades

Murray, Patty

U.S. Sen. · 181 trades

Frequently asked

How many insider trades does FilingIQ track for BMY?: FilingIQ tracks 2,247 Form 4 insider transactions for BMY (BRISTOL MYERS SQUIBB CO), covering filings from Mar 10, 2015 onwards. 185 of those were filed in the last 90 days.
Are BMY insiders net buyers or net sellers?: Across the full Form 4 history for BMY, 14 transactions (1%) were open-market purchases and 109 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BMY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BMY in?: BRISTOL MYERS SQUIBB CO (BMY) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $125.41B.

Methodology & sources

Every BMY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.